Please assess the completion status of the following clinical trial:

Trial Title: Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male participants~* Between the ages of 18 and 50~* Meet diagnostic criteria for schizophrenia or schizoaffective disorder~* Are clinically stable for a minimum of 3 months on current dose of medication~* Are unemployed (i.e., work less than 20 hours per week at competitive employment)~Exclusion Criteria:~* Psychoactive substance dependence within the past 6 months or substance abuse within the past month~* History of head trauma or other neurological disorder~* Medical illness or medications, such as benzodiazepine treatment or HIV medications, that may be affected by study participation (the study doctor will discuss this with potential subjects)~* Mental retardation~* Seizure disorder~* History of a heart attack, arrhythmia, or other heart disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Merck L-830982 (Type: EXPERIMENTAL): None
- Sugar pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).